Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5‐A3‐B4) predict severity of nicotine addiction and response to smoking cessation therapy
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Stopping smoking is difficult even with treatment. Many patients prescribed pharmacologic treatments for smoking cessation experience side effects or lack of efficacy. We performed a pharmacogenetic study of the efficacy and tolerability of bupropion and transdermal nicotine (TN), two treatments for smoking cessation. Samples were drawn from two studies. In the first study (Maintenance 1, MT1), 301 smokers received bupropion plus TN for 11 weeks, followed by 14 weeks of placebo or bupropion. In the second study (MT2), 276 smokers received bupropion and TN for 8 weeks. We focused on eight SNPs in the 15q24 region, which contains the genes for the nicotinic cholinergic receptor subunits CHRNA5, CHRNA3, and CHRNB4, and has previously been implicated in nicotine addiction and smoking cessation. Analyses of baseline smoking quantity (SQ) identified an association between SQ and both the functional CHRNA5 SNP rs16969968 (D398N) and the CHRNA3 SNP rs1051730 (Y215Y) in a combined cohort containing MT1 and MT2. An association between SQ and ethnicity was also identified in the combined cohort. Pharmacogenetic analysis showed a significant association between rs8192475 (R37H) in CHRNA3 and both higher craving after quitting and increased withdrawal symptoms over time in MT2. Two markers for point prevalence abstinence, CHRNA5 SNP rs680244 and CHRNB4 SNP rs12914008, were also identified in MT2, with the strongest findings at week 52. These results provide further support for the role of the CHRNA5/A3/B4 subunits in determining number of cigarettes smoked and response to smoking cessation therapy. © 2011 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fagerström, K.-O. (1978) · Addictive Behaviors · doi:10.1016/0306-4603(78)90024-2 · Cited by 2,221 · cited 1×
“Analyses of genetic markers as predictors of baseline SQ and baseline addiction, based on the modified Fagerstrom Test of Nicotine Dependence score (mFTQ) [Fagerstrom, 1978; Killen et al., 1988], were tested by regression analysis using a model similar to that used in Thorgeirsson et al. [2008].”
MethodA variant associated with nicotine dependence, lung cancer and peripheral arterial disease
Thorgeirsson, T. E., Geller, F., Sulem, P., Rafnar, T., Wiste, A., Magnusson, K. P., Manolescu, A., Thorleifsson, G., Stefansson, H., Ingason, A., et al. (2008) · Nature · doi:10.1038/nature06846 · Cited by 1,523 · cited 4×
“…diseases, including lung cancers andperipheral vascular disease [Amos et al., 2008;Hung et al., 2008; LeMarchand et al., 2008; Spitz et al., 2008; Thorgeirsson et al., 2008; Falvella et al., 2009; Wang et al., 2009a], and a number of other forms of addiction [Grucza et al., 2008; Chen et al.,…”
BackgroundInfluentialAmos, C. I., Wu, X., Broderick, P., Gorlov, I. P., Gu, J., Eisen, T., Dong, Q., Zhang, Q., Gu, X., Vijayakrishnan, J., et al. (2008) · Nature Genetics · doi:10.1038/ng.109 · Cited by 1,310
Hung, R. J., McKay, J. D., Gaborieau, V., Boffetta, P., Hashibe, M., Zaridze, D., Mukeria, A., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P., et al. (2008) · Nature · doi:10.1038/nature06885 · Cited by 1,275 · cited 2×
“This region has also been associated with smoking-related diseases, including lung cancers andperipheral vascular disease [Amos et al., 2008;Hung et al., 2008; LeMarchand et al., 2008; Spitz et al., 2008; Thorgeirsson et al., 2008; Falvella et al., 2009; Wang et al., 2009a], and a number of other…”
BackgroundThe development and initial validation of a questionnaire on smoking urges
TIFFANY, S. T., & DROBES, D. J. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01732.x · Cited by 974
Saccone, S. F., Hinrichs, A. L., Saccone, N. L., Chase, G. A., Konvicka, K., Madden, P. A. F., Breslau, N., Johnson, E. O., Hatsukami, D., Pomerleau, O., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl438 · Cited by 850 · cited 1×
“There were no significant genetic predictors of baseline mFTQ, despite previous associations between markers in the 15q24 region andnicotine dependence [Weiss et al., 2008; Baker et al., 2009;Chen et al., 2009; Saccone et al., 2007].”
BackgroundVariants in Nicotinic Receptors and Risk for Nicotine Dependence
Bierut, L. J., Stitzel, J. A., Wang, J. C., Hinrichs, A. L., Grucza, R. A., Xuei, X., Saccone, N. L., Saccone, S. F., Bertelsen, S., Fox, L., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111711 · Cited by 648 · cited 6×
“frequencies among ethnic groups that has previously been reported within this region [Bierut et al., 2008; Saccone et al., 2008].”
BackgroundResultInfluentialBupropion is a nicotinic antagonist
Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509
Zoli, M., Moretti, M., Zanardi, A., McIntosh, J. M., Clementi, F., & Gotti, C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08785.2002 · Cited by 407 · cited 2×
“…of particular interest because it contributes to the a4b2a5 nicotinic receptor, which is involved in nicotine-stimulated dopamine release in the striatum, a brain region involved in the reward pathway and crucial to the development of substance dependence [Zoli et al., 2002; Salminen et al., 2004].”
BackgroundFryer, J. D., & Lukas, R. J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37928-5 · Cited by 283
Cited by
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub4 · Cited by 348
McEvoy, C. T., & Spindel, E. R. (2017) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2016.08.005 · Cited by 256
McEvoy, C. T., Schilling, D., Clay, N., Jackson, K., Go, M. D., Spitale, P., Bunten, C., Leiva, M., Gonzales, D., Hollister-Smith, J., et al. (2014) · JAMA · doi:10.1001/jama.2014.5217 · Cited by 217
McLaughlin, I., Dani, J. A., & De Biasi, M. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/978-3-319-13482-6_4 · Cited by 191
“The rs8192475 variant in CHRNA3 was shown to predict withdrawal symptoms and craving after quitting (Sarginson et al. 2011).”
BackgroundSpindel, E. R., & McEvoy, C. T. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-2013pp · Cited by 154
“Smoking in pregnancy is a unique morbidity in that smoking is addictive, heavily advertised (24, 25), and, as discussed below, certain genotypes significantly increase the likelihood of nicotine addiction/failure to quit (26, 27).”
BackgroundA CHRNA5 smoking risk variant decreases the aversive effects of nicotine in humans
Jensen, K. P., DeVito, E. E., Herman, A. I., Valentine, G. W., Gelernter, J., & Sofuoglu, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.131 · Cited by 85
Antidepressants for smoking cessation
Hajizadeh, A., Howes, S., Theodoulou, A., Klemperer, E., Hartmann-Boyce, J., Livingstone-Banks, J., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub6 · Cited by 84
From Men to Mice: CHRNA5/CHRNA3, Smoking Behavior and Disease
Ware, J. J., van den Bree, M., & Munafò, M. R. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/nts106 · Cited by 62
Metadata
- Authors
- Sarginson, J. E., Killen, J. D., Lazzeroni, L. C., Fortmann, S. P., Ryan, H. S., Schatzberg, A. F., & Murphy, G. M.
- Venue
- American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Publisher
- Wiley
- Published
- 2011-01-25
- Volume
- 156
- Issue
- 3
- Pages
- 275-284
- ISSN
- 1552-4841 (ISSN-L)
- 1552-485X
- OpenAlex
- W2011273512
- Cited by
- 92
- References
- 21
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.